vimarsana.com
Home
Live Updates
Sarepta Rebounded. Its Gene Therapy Is Back on Course. : vim
Sarepta Rebounded. Its Gene Therapy Is Back on Course. : vim
Sarepta Rebounded. Its Gene Therapy Is Back on Course.
The future of Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy looked grim two months ago. There’s been a 180 since.
Related Keywords
San Francisco ,
California ,
United States ,
Josh Nathan Kazis ,
Doug Ingram ,
Kristen Kluska ,
Tim Lugo ,
Peter Marks ,
William Blair ,
Josephp Schwartz ,
Drug Administration ,
Schwartz ,
Cantor Fitzgerald ,
Sarepta Therapeutics ,
Biologics Evaluation ,
Article Normal ,
Biotechnology Services ,
Pharmaceuticals ,
Semiconductors ,
Healthcare Life Sciences ,
Biopharmaceuticals ,
Biological Therapy ,
Industrial Electronics ,
Industrial Goods ,
Integrated Circuits ,
Healthcare Provision ,
Technology ,
Regulation Government Policy ,
Corporate Industrial News ,
Political General News ,
Health ,
Genetic Disorders ,
Medical Conditions ,
Medical Treatments Procedures ,
Content Types ,
Factiva Filters ,
C Amp Ampe Industry News Filter ,
Synd ,
Barron Amp 39s Take ,
Biotech And Pharma ,
Healthcare ,
Srpt ,
Spdrs Amp Ampp Biotech Etf ,
Xbi ,
Regulation ,
Government Policy ,
Corporate ,
Industrial News ,
Political ,
General News ,
Medical Treatments ,
Procedures ,
Life Sciences ,